PBAC's latest decision on Docetaxel: Recommended (2017). Considered for Treatment of castrate-resistant metastatic prostate cancer; also indicated for other malignancies including breast cancer and non-small cell lung cancer (per existing PBS listings).
PBAC outcome
Recommended
Unrestricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
8
first 2005
Submissions
8
2005 → 2017
Eligible population
Adults with castrate-resistant metastatic prostate cancer; also other malignancies for which docetaxel is indicated on the PBS.
Therapy area
Oncology
Line of therapy
Any
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Economic model
Cost-minimisation
ICER note
Minor submission (formulation change only); no new economic evaluation conducted. Cost-neutral to PBS.
ICER (historical)
$45k/QALY–$75k/QALY across 5 submissions (2005–2007) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.